ABUS Valuation

Arbutus Biopharma Corp

Add to Watchlist

Advanced Chart

3.220

-0.02(-0.617%)1D

Overview
Forecast
Valuation
Earnings

ABUS Relative Valuation

ABUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABUS is overvalued; if below, it's undervalued.

Historical Valuation

Arbutus Biopharma Corp (ABUS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 116.57 is considered Overvalued compared with the five-year average of -6.63. The fair price of Arbutus Biopharma Corp (ABUS) is between 0.34 to 1.97 according to relative valuation methord. Compared to the current price of 3.22 USD , Arbutus Biopharma Corp is Overvalued By 63.37%.

Relative Value

Fair Zone

0.34-1.97

Current Price：3.22

63.37%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

7.79

P/B

Median3y

4.36

Median5y

0.71

-9.51

FCF Yield

Median3y

-14.57

Median5y

-15.16

Competitors Valuation Multiple

The average P/S ratio for ABUS's competitors is 21.97, providing a benchmark for relative valuation. Arbutus Biopharma Corp Corp (ABUS) exhibits a P/S ratio of 116.57, which is 430.70% above the industry average. Given its robust revenue growth of 15.14%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ABUS.O

Arbutus Biopharma Corp

116.57

Average P/S: 21.97

15.14%